Mather Group’s Vir Biotechnology VIR Stock Holding History

Mather Group’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-70	Closed	-$709	–	2209
2024 Q2	$709	Buy	+70	New	+$671	﹤0.01%	2034

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Mather Group's VIR Position: Q3 2024 in Review

Mather Group sold out of Vir Biotechnology (VIR) in Q3 2024, closing a stake of 70 shares — an estimated $709 sold.

Mather Group first reported a position in VIR in Q2 2024 and held it in 1 quarter. The position peaked at $709 in Q2 2024. 197 funds tracked by Wall St. Rank hold VIR as of Q3 2024.

Mather Group reported no remaining Vir Biotechnology position as of Q3 2024 after selling out during the quarter.
Mather Group sold 70 Vir Biotechnology shares in Q3 2024, an estimated $709.
Mather Group first reported a position in Vir Biotechnology in Q2 2024 and held it in 1 quarter.
Mather Group's Vir Biotechnology position peaked at $709 in Q2 2024.
197 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2024.

Based on Mather Group's 13F filing for Q3 2024, filed 7 Oct 2024.